ATE427317T1 - Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane - Google Patents

Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane

Info

Publication number
ATE427317T1
ATE427317T1 AT02756777T AT02756777T ATE427317T1 AT E427317 T1 ATE427317 T1 AT E427317T1 AT 02756777 T AT02756777 T AT 02756777T AT 02756777 T AT02756777 T AT 02756777T AT E427317 T1 ATE427317 T1 AT E427317T1
Authority
AT
Austria
Prior art keywords
neuregulin
targeted
heparin binding
proteoglycan
hybrid proteins
Prior art date
Application number
AT02756777T
Other languages
English (en)
Inventor
Jeffrey Loeb
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Application granted granted Critical
Publication of ATE427317T1 publication Critical patent/ATE427317T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT02756777T 2001-07-31 2002-07-31 Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane ATE427317T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30856301P 2001-07-31 2001-07-31

Publications (1)

Publication Number Publication Date
ATE427317T1 true ATE427317T1 (de) 2009-04-15

Family

ID=23194471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756777T ATE427317T1 (de) 2001-07-31 2002-07-31 Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane

Country Status (8)

Country Link
US (1) US7527794B2 (de)
EP (1) EP1456239B1 (de)
JP (1) JP4314113B2 (de)
AT (1) ATE427317T1 (de)
AU (1) AU2002322762B2 (de)
CA (1) CA2455830C (de)
DE (1) DE60231833D1 (de)
WO (1) WO2003012045A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4955548B2 (ja) * 2004-07-09 2012-06-20 ウェイン・ステイト・ユニバーシティ 標的化のためのＥｒｂＢ４細胞外ドメインおよびニューレグリンヘパリン結合ドメインを有するハイブリッドタンパク質
WO2009072005A2 (en) * 2007-10-15 2009-06-11 Centre National De La Recherche Scientifique - C.N.R.S. Cxcl12 gamma a chemokine and uses thereof
EP2346526A2 (de) 2008-09-22 2011-07-27 Massachusetts Institute of Technology Zusammensetzungen und verfahren zur verwendung von liganden-dimeren
EP2555788B1 (de) 2010-03-24 2017-10-11 Massachusetts Institute of Technology Neuregulin dimer für einen erbb/her rezeptor für die verwendung in reduzierung der kardiotoxizität
CN103118698A (zh) * 2010-05-28 2013-05-22 意识-Nrg公司 神经调节素同种型，神经调节素多肽和其使用
WO2012177653A2 (en) * 2011-06-20 2012-12-27 St. Louis University Targeting the neuromuscular junction for treatment
US20130058871A1 (en) * 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
CA2877886A1 (en) 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Targeted therapeutics comprising heparin binding protein
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
US20170333529A1 (en) * 2015-01-20 2017-11-23 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
US11143659B2 (en) 2015-01-27 2021-10-12 Arterez, Inc. Biomarkers of vascular disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007935A1 (en) 1990-11-01 1992-05-14 The Scripps Research Institute Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
JPH08502168A (ja) 1992-09-29 1996-03-12 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞においてイオンチャンネル誘導活性をもつ栄養因子
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
WO1997009051A1 (en) 1995-09-05 1997-03-13 Cambridge Neuroscience, Inc. Analogs for specific oligosaccharide-neuregulin interactions and uses thereof
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
DE69740038D1 (de) 1996-07-12 2010-12-16 Genentech Inc
CA2257839C (en) * 1996-07-12 2012-10-23 Genentech, Inc. Gamma-heregulin
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
WO1998043649A2 (en) 1997-03-28 1998-10-08 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?
AU4469997A (en) 1997-09-17 1999-04-05 Urs Eppenberger Heregulin-gamma
WO1999055351A1 (en) 1998-04-23 1999-11-04 Vladimir Leko Herbal composition and medicament against diabetes mellitus type ii manufactured thereof
ES2267494T3 (es) 1999-01-29 2007-03-16 Kaneka Corporation Procedimiento para la preparacion de derivados de treo-1,2-epoxi-3-amino-4-fenilbutano.

Also Published As

Publication number Publication date
AU2002322762B2 (en) 2008-10-16
EP1456239A4 (de) 2005-04-27
US20050107601A1 (en) 2005-05-19
JP4314113B2 (ja) 2009-08-12
DE60231833D1 (de) 2009-05-14
CA2455830A1 (en) 2003-02-13
JP2005500052A (ja) 2005-01-06
WO2003012045A3 (en) 2004-07-01
EP1456239B1 (de) 2009-04-01
EP1456239A2 (de) 2004-09-15
CA2455830C (en) 2012-10-09
WO2003012045A2 (en) 2003-02-13
US7527794B2 (en) 2009-05-05

Similar Documents

Publication Publication Date Title
NO20001600D0 (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
DE69738483D1 (de) Polypeptide mit phytase-aktivität und sie kodierende nukleinsäuren
NO20001599L (no) Apolipoprotein A-1 agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
ATE427317T1 (de) Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane
PL341524A1 (en) Novel receptor coupled wih g protein
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
NZ595498A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE323770T1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
WO2006017184A3 (en) HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING
EA199900522A1 (ru) Полипептиды, кодируемые геном, подобным гену липазы человека, композиции и методы
TR200200253T2 (tr) Proteinlerin üretimi
ATE295890T1 (de) Vektor zur expression von n-terminal verlängerten proteinen in hefezellen
Klatt et al. The matrilin-3 VWA1 domain modulates interleukin-6 release from primary human chondrocytes
WO2003057708A3 (en) Fusion proteins
Qiang et al. Discovery of a Novel Cysteine Framework XXIV Conotoxin from Conus Striatus, S24a, with Potential Analgesic Activity
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
ATE260339T1 (de) Antikörper gegen menschliches restrictin
MXPA02011938A (es) Adn que codifica para un receptor de histamina de mamifero del subtipo h4.
ATE317896T1 (de) Polypeptide mit glucanotransferase aktivität und dafür kodierende nukleinsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties